Martin J. van den Bent, MD, PhD | Authors

Articles

ABT-414 Shows Promise Against EGFR-Amplified Glioblastoma

November 21, 2016

In this interview we discuss findings from M12-356, an open-label, phase I, escalation cohort study of the investigational anti-EGFR antibody-drug conjugate ABT-414 for patients with EGFR-amplified recurrent glioblastoma.